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Available online 21 August 2004Aims Magnetic resonance (MR) first-pass myocardial perfusion imaging during hypera-
emia detects coronary artery stenoses in humans with test sensitivity depending on
contrast medium (CM)-induced signal change in myocardium. In this prospective
multi-centre study, the effect of CM dose on myocardial signal change and on diagnos-
tic performance was evaluated using a stress-only approach.
Methods and results Ninety-four patients with known or suspected coronary artery
disease (CAD) were randomised to 0.05,0.10, or 0.15 mmol/kg body weight of an ex-
travascular CM (Gd-DTPA) and X-ray coronary angiography was performed within 30
days prior/after the MR examination. A multi-slice MR technique with identical hard-
ware and software in all centres was used during hyperaemia (adenosine 0.14 mg/kg/
min) to monitor myocardial CM wash-in kinetics and data were analysed semi-auto-
matically in a core laboratory. Protocol violations resulted in 80 complete studies
with CAD (defined as P 1 vessel with diameter stenosis P 50% on quantitative coro-
nary angiography) present in 19/29, 13/24, and 20/27 patients for doses 1, 2, and 3,
respectively. In normal myocardium, the upslope increased with CM dose (overall-
p < 0.0001, ANOVA). For CAD detection the area under the receiver operator charac-
teristics curve for subendocardial data (3 slices with quality score < 4 representing
86% of cases) was 0.91 ± 0.07 and 0.86 ± 0.08 for doses 2 and 3, respectively, and
was lower for dose 1 (0.53 ± 0.13, p < 0.01 and p < 0.02 vs. doses 2 and 3, respec-
tively). Corresponding sensitivities/specificities (95% confidence intervals) for pooled
doses 2/3 were 93% (77–99%; ns vs. dose 1) and 75% (48–92%; p < 0.05 vs. dose 1),
respectively.
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1658 T.H. Giang et al.Conclusions With increasing doses of CM, a higher signal response in the myocardium
was achieved and consequently this stress-only protocol, with CM doses of 0.10–0.15
mmol/kg combined with a semi-automatic analysis, yielded a high diagnostic perfor-
mance for the detection of CAD.c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.Introduction
In recent years MR perfusion imaging has emerged as an
alternative tool to study regional myocardial perfusion,
but several conceptual and technical aspects of the im-
aging protocol remain controversial. In MR perfusion
studies, hypoperfused myocardium shows delayed
contrast medium (CM) wash-in kinetics during first-
pass.1–6 Since detection of hypoperfused myocardium
is facilitated by augmenting the difference between
first-pass signal change in normal vs. hypoperfused
myocardium,7 i.e., by increasing the dynamic range of
signal response in normal myocardium, pulse sequence
parameters and dose of CM are important to maximize
peak signal in normal myocardium during first-pass.
Typically, doses of 0.025 mmol/kg,4 0.03 mmol/kg,8
0.04 mmol/kg,9 0.05 mmol/kg,6 and 0.1 mmol/k7,10
were used for first-pass MR perfusion imaging in hu-
mans. While high CM doses may increase the dynamic
range of myocardial signal response, susceptibility arte-
facts at higher doses could cause signal loss and result
in false positive findings. Patients were therefore ran-
domly assigned to 0.05, 0.10, and 0.15 mmol/kg of
an extravascular CM. Here, we were particularly inter-
ested to determine the dose with best performance
when data were analysed semi-automatically, i.e., with
minimal observer interference (i.e., data registration
and contour drawing only). As a measure of perfusion,
this analysis yielded signal change/time (i.e., the ups-
lope) which was shown to correlate well with myocar-
dial perfusion.1,10 Based on previous reports6,10
suggesting that the subendocardial layer is the most
sensitive to ischaemia, all analyses were performed in
the subendocardial layer and for full wall thickness.
In a recent single centre MR perfusion study10 hyperae-
mic data alone allowed for reliable stenosis detection.
Such a stress-only approach is advantageous in compari-
son to rest-stress protocols, since it shortens both time
for examination and analysis. Finally, to address the im-
pact of data quality on test performance, data from 3 dif-
ferent MR centres were entered into this study.Methods
Study population
Ninety-four patients scheduled for coronary angiography were
enrolled in 3 centres in order to assess the diagnostic efficacy
of 3 doses of an extravascular CM. Coronary angiography wasindicated in the presence of clinical suspicion (based on symp-
toms and/or positive findings of ischaemia testing with con-
ventional methods) or as part of routine work-up prior to
surgery of the great vessels. This resulted in a prevalence of
65% for CAD (defined as P 50% diameter stenosis in any coro-
nary artery) which reflects the typical population undergoing
coronary angiography in these centres. Exclusion criteria in
this open-label phase II trial were recent myocardial infarction
(<2 weeks prior to enrollment), unstable angina, atrial fibrilla-
tion, 2nd/3rd degree AV block, and previous coronary artery by-
pass grafting.
Patients were randomised (balanced for each centre) to ei-
ther 0.05, 0.10, or 0.15 mmol/kg body weight of Gd-DTPA
(Magnevist, Berlex Laboratories, NJ, USA). X-ray coronary angi-
ography was performed within 30 days prior/after the MR study
(without any interventions or changes in symptoms between the
studies). Antianginal medication was withdrawn P 24 h before
the MR study as were caffeinated beverages or food. During
the 2 h prior to and immediately after the MR examination, as
well as 2–4 and 24 h later, vital signs and 12-lead ECG recordings
were performed. Blood samples were collected prior to and 2–4
and 24 h after the MR examination.
The study protocol was approved by the local Ethics Com-
mittees and all subjects gave written informed consent prior
to study participation. MR and angiographic data were
analysed and stored without knowledge of the patients
history, symptoms, or findings obtained during the other
procedures.MR examination
All subjects were examined in the supine position using 1.5T
MR scanners (CV/i, General Electric, Milwaukee, WI, USA),
identical phased-array receiver coils, ECG-triggering devices,
and the same pulse sequence software.11 Following 3 min of
adenosine infusion (0.14 mg/kg/min), Gd-DTPA was injected
into a cubital vein at 5 mL/s (Spectris, Medrad, Indianola,
PA, USA), and adenosine was stopped after first-pass data ac-
quisition. Coincident with initiation of imaging and CM injec-
tion, the patient held his/her breath to reduce motion
artefacts during first-pass. Peak CM effect was achieved at ap-
proximately 20 heart beats, while total acquisition lasted 60
heart beats. CM first-pass through the heart was monitored us-
ing a hybrid echo-planar pulse sequence (TR 6.6–15.8 ms, TE
1.3–2.2 ms, delay time (=time between 90 preparation pulse
and read-out): 158–211 ms, echo-train length 4–8, field-of-
view 34–37 · 25–27 cm, matrix 128 · 128, slice thickness 10
mm, and read-out flip angle 25). Depending on heart rate,
6–8 interleaved short-axis slices were acquired over two full
R–R intervals (systole and diastole).11 During the MR study
blood pressure and heart rate were acquired at 2, 5, 15, 30,
60 min after CM administration. Two-lead ECG, respiratory
rate, and oxygen saturation were monitored continuously
(Model 9500, MR Equipment, Bay Shore, NY).
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging 1659Data analysis
MR data analysis was performed in a core laboratory by an expe-
rienced observer blinded to any clinical or invasive data. To cor-
rect for gross cardiac motion, several anatomic landmarks
(epicardial/endocardial borders, papillary muscles) were
aligned manually using a home-written software. Quality of
the registered data was assessed by 2 blinded readers by consen-
sus using a 14-point scoring system; 2 points each were assigned
to residual motion during CM wash-in, ghosts along phase-encod-
ing, and susceptibility, 1 point was assigned to motion after CM
wash-in, blurring along phase-encoding, double contours, extra
systoles, and blood pool or coronary arteries included in myocar-
dial drawings. With this rating a score P 4 defined visually non-
evaluable studies. Epicardial and endocardial contours were
drawn on the registered images (excluding papillary muscles)
and eight equiangular segments/slice were generated automat-
ically (rotating clockwise using the anterior septal insertion of
the right ventricle as a reference).10 The maximum upslope (5-
point linear fit, sliding window) was calculated for full wall
thickness and the inner half, i.e., the subendocardial layer, in
48–64 segments/heart (depending on the number of slices
acquired).
In order to evaluate the effect of the 3 CM doses on signal in-
crease in normalmyocardium, absolute upslope values in the sub-
endocardial and transmural segments were calculated in the
patients without CAD (diameter stenoses < 50% on quantitative
coronary angiography; QCA). To correct for surface coil inhomo-
geneity, relative upslope valueswere calculatedby dividing signal
change during first-pass by the pre-contrast signal.Receiver operator characteristics of MR
perfusion imaging vs. X-ray coronary angiography
CAD was defined as P 1 stenosis P 50% in diameter in any of the
3 coronary arteries (and their side branches with a diameter P 2
mm) on QCA (Philips Inturies, R2.2). QCA was performed on-site
with the observers blinded to all clinical and MR data (data from
the University Hospital Cambridge were analysed in the Univer-
sity Hospital Zurich for logistical reasons).
Since aminimumof 6 sliceswas acquired in all patients and the
first slice had inconsistent preparation (see Fig. 1(c)/(g)/(l)), 5
slices were used for ROC analyses, whichwere performed on a pa-
tient basis (i.e., P 1 segment of a total of 40 segments/heart be-
low threshold was required to define the presence of CAD in a
patient on MR). To assess the diagnostic performance of subendo-
cardial and transmural upslope data, ROC curves were generated
from 100 sensitivity/specificity pairs per dose by generating 100
thresholds per dose defined as slopenorm  x Æ SD with x increasing
in steps of 0.1, and slopenorm being the normalised slope; since 3
different CM doses were used in this study, upslopes in normal
myocardium (=patientswithout CAD)were expressed as a fraction
of the mean upslope value for each dose. Through this normalisa-
tion, slopenorm of the 3 CM dose groups becomes interchangable,
i.e., for the thresholds for dose 1, slopenorm was calculated as
the mean of slopenorm from the patients without CAD of dose 2
(n = 11) and 3 (n = 7). Thus, no data of dose 1 were used to gener-
ate threshold values for the calculation of ROC curves of dose 1. In
analogy, for ROC analysis of dose 2, slopenorm was calculated as
means of slopenorm from the patients without CAD of dose 1
(n = 10) and 3 (n = 7). For ROCanalysis of dose 3, slopenormwas cal-
culated as means of slopenorm from the patients without CAD of
dose 1 (n = 10) and 2 (n = 11). Finally, slopenorm.endo ± SD and
slopenorm.trans ± SD refer to mean slopes ± SD derived from the
subendocardial layer and from full wall thickness, respectively.All ROCanalyseswereperformed for subendocardial and transmu-
ral upslopes of 5 slices (=entire stack) and of the central 3 slices.
Calculations were repeated after eliminating studies with lowest
imagequality (=quality score P 4). These datawere also analysed
by a second observer to determine reproducibility.
Diagnostic performance of MR perfusion imaging was also as-
sessed in single and multi-vessel disease and for various coro-
nary arteries (with segments 1 and 8 assigned to the left
anterior descending coronary artery, segment 3 to the left cir-
cumflex, and segments 5 and 6 to the right coronary artery
and their corresponding branches10).Statistical analysis
Values are given as mean ± SD. To compare absolute and relative
signal changes as well as upslope data in the various segments
and slices for the 3 CM doses an ANOVA for repeated measure-
ments was performed (within factors: segments or slices, be-
tween factor: CM dose) followed by Scheffe’s post hoc testing.
Sensitivities and specificities including 95% confidence intervals
were calculated on a patient basis with an exact binomial test.
Comparisons between doses for sensitivities and specificities
were performed by Fisher’s exact test. ROC curves were gener-
ated as described above on a patient basis and were compared
according to Hanley et al.,12,13 followed by Bonferroni-correc-
tion to address the problem of multiple comparisons
(p < 0.017 = significant). All tests were 2-sided and a p < 0.05
was considered statistically significant.
Measuring an expected difference in upslope between dose
groups of approximately 10%/s11 with an inter-observer repro-
ducibility of approximately 10%/s10 in 3 groups with 30 patients
each was calculated to yield an estimated power of 91% to de-
tect differences at a p-value of 0.017 (=0.05/3).Results
In 14 patients out of 94, data were incomplete due to in-
correct study protocol in 10 (6 uncorrected MR pulse se-
quences, 4 missing coronary angiography), 2 images lost
before archiving, paravenous CM administration and 1
claustrophobia. No serious adverse events were
reported. Demographics and haemodynamics are given
in Table 1. No patients with persistent left bundle branch
block were studied.Myocardial signal response in normal
myocardium
Fig. 1 shows the signal intensity–time curves in normal
myocardium (patients without CAD on QCA) for all 3 CM
doses. Fig. 1(a)/(e)/(i) demonstrates the typical effect
of inhomogeneous coil sensitivity causing reduced signal
reception from segments distant from the coil (seg-
ments 4–6). An efficient correction for signal differenc-
es between segments is achieved by division of the
first-pass signal intensity by the pre-contrast signal in-
tensity (Fig. 1(b)/(f)/(k)). This procedure also corrects
for different distances of the various myocardial slices
from the receiver coil (Fig. 1(c)/(g)/(l)). However, this
approach does not fully account for different signal
Fig. 1 Signal intensity-time curves in normal myocardium for all 3 contrast medium doses are shown. Absolute signal change (peak signal – pre-contrast
signal) in anterior and antero-septal segments (1, 2 and 7, 8, respectively) located closely to the surface coil is high in comparison with the more distant
segments 3–6 (a/e/i). Relative signal change (b/f/k) corrects for response differences in the various segments. Relative signal change also corrects for
response differences between slices 2–6, but not for slice 1 (p < 0.0001 vs. all other slices; c/g/l). Finally, Figure1d/h/m demonstrates that no
susceptibility-induced signal loss occurs in the subendocardium even at the highest dose of 0.15 mmol/kg of Gd-DTPA. The grey areas represent ±1 SD of
the curves of all patients (without coronary stenoses) for segments 1–8 (all slices/heart averaged, panels a/b/e/f/i/k), for slices 2–6 (all segments/
heart averaged, c/g/l), and for subendocardial and full thickness data (all segments/heart averaged, d/h/m). *p < 0.02 vs. dose 1; §p < 0.002 vs. dose 1,
&p < 0.0001 vs. dose 1, #p < 0.05 vs. dose 1 (repeated measures ANOVA with Scheffe post hoc testing). Significance levels in (h) and (m) apply for both,
subendocardial and full wall thickness data.
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where the magnetisation preparation differs from that
of the other slices. Finally, Fig. 1(d)/(h)/(m) demon-
strates that signal increase in the subendocardial layer
is not different from full wall thickness data for all
doses. Even at the highest dose of 0.15 mmol/kg (Fig.
1(m)), no susceptibility-induced signal loss, but a
further increase in signal in the subendocardium is
noted (p < 0.02 vs.0.10 mmol/kg, ANOVA with Scheffes
post hoc testing). As shown for signal change, upslope
values (%signal change/s) also increased with increasing
CM doses. For doses 1,2, and 3 in the subendocardium:
24.9 ± 9.0%/s, 37.0 ± 6.3%/s (p < 0.02 vs. dose 3; p = 0.6
vs. dose 1), and 47.4 ± 14.9%/s (p < 0.0001 vs. dose 1),
respectively.Diagnostic performance of MR perfusion imaging
For the dose groups 1–3, mean quality scores were similar
(1.9 ± 1.6; 2.2 ± 1.6; and 1.6 ± 1.4, respectively, not sig-
nificant). A total of 11 studies (14%, 17%, and 11% for dose
groups 1–3, respectively) were deemed non-evaluable by
visual assessment (score P 4; 14% of all studies, nosignificant differences for the 3 centres). ROC analyses
were performed on both, patients with adequate quality
(n = 69; score < 4) and on the entire data set.
Best diagnostic performance was achieved for doses 2
and 3 in studies with adequate quality (score < 4) when
analysis was restricted to the 3 central slices (subendo-
cardial data, Fig. 2(a)). Sensitivity and specificity (abso-
lute numbers and 95% confidence intervals in
parenthesis) for dose 2 were 91% (10/11; 59–100%) and
78% (7/9; 40–97%), respectively, and for dose 3, 94%
(16/17; 71–100%) and 71% (5/7; 29–96%), respectively.
For dose 1, at a comparable sensitivity level of 94%
(16/17; 71–100%, ns vs. doses 2 and 3), specificity was
only 25% (2/8; 3–65%, p = 0.057 vs. dose 2, p = 0.13 vs.
dose 3). For the pooled doses 2 and 3 (subendocardial da-
ta), sensitivity and specificity were 93% (26/28; 77–99%,
ns vs. dose 1) and 75% (12/16; 48–92%, p > 0.05 vs. dose
1), respectively. Negative/positive predictive values for
doses 1, 2, and 3 were 73/67%, 88/83% and 83/89%,
respectively.
With respect to data quality, most artefacts were mo-
tion-related (82% of all images with a score P 4). Cardiac
coverage may affect data quality by increasing partial
volume artefacts in apical slices or by including atria
Table 1 Patient demographics
Dose 1 (0.05 mmol/kg) Dose 2 (0.10 mmol/kg) Dose 3 (0.15 mmol/kg)
Total: n 29 24 27
Age (years) 58 ± 8 57 ± 9 58 ± 10
Gender (male/female) 25/4 16/8 24/3
Body weight (kg) 80 ± 11 76 ± 11 81 ± 15
Risk factors
hypertension 13 (45) 7 (29) 11 (41)
Hypercholesterolemia 17 (59) 11 (46) 17 (63)
Smoking 10 (34) 8 (33) 10 (37)
Diabetes mellitus 4 (14) 3 (13) 5 (19)
Family history 5 (17) 4 (17) 4 (15)
Prior myocardial infarctions 11 (38) 7 (29) 10 (37)
History of heart failure 0 (0) 3 (13) 1 (4)
Atypical or no chest pain 2 (7) 2 (8) 2 (7)
Angina pectoris
CCS I 14 (48) 10 (42) 10 (37)
CCS II 8 (28) 11 (46) 9 (33)
CCS III 5 (17) 3 (13) 4 (15)
CAD
1-CAD 10 (34) 9 (38) 11 (41)
2-CAD 8 (28) 2 (8) 3 (11)
3-CAD 1 (3) 2 (8) 6 (22)
Prior PCI 3 (10) 6 (25) 8 (30)
Time to MR in months: range [mean] 6–7 [6.3] 3–65 [24.7]a 3–7 [5.7]
Correct diagnosis by MR 1 6 6
Therapyb
Conservative therapy only 12 (41) 10 (42) 15 (56)
PCI 10 (34) 9 (38) 8 (30)
CABG 5 (17) 4 (17) 4 (15)
Resting condition
Heart rate (bpm) 67 ± 10 68 ± 11 67 ± 9
Systolic BP (mmHg) 145 ± 21 142 ± 21 149 ± 22
Diastolic BP (mmHg) 81 ± 10 80 ± 12 81 ± 12
Stress conditionc
heart rate (bpm) 72 ± 13 75 ± 15 75 ± 13
systolic BP (mmHg) 142 ± 23 143 ± 24 146 ± 28
diastolic BP (mmHg) 78 ± 11 77 ± 12 80 ± 12
Numbers in parentheses represent percentages. No statistically significant differences between dose groups were present.
a In one patient a percutaneous coronary intervention (PCI) was performed 2 days prior to MR which yielded correct results.
b Therapy following coronary angiography and MR examination.
c At 2 min after end of adenosine infusion. bpm, beats/min; BP, blood pressure; CABG, coronary artery bypass grafting; 1-, 2-, 3-CAD, single-, double-,
tripple-vessel coronary artery disease; CCS, Canadian Cardiovascular Society. All patients were taking acetyl salicylic acid and statins if indicated.
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septum in basal slices. When control of artefacts was less
strict by either analysing the entire stack of slices (Fig.
2(c)) or by including images of all quality scores (Fig.
2(b)), performance of dose 2 tended to deteriorate (ns
vs. dose 2 in Fig. 2(a)). When control of artefacts was
lowest (analysis of entire stack of slices for all quality
scores, Fig. 2(d)) AUC for dose 2 decreased further
(p < 0.05 vs. dose 2 with 3 slices and score < 4, Fig.
2(a)). Dose 1 performed poor under all circumstances.
Dose 3 appeared most robust with high AUCs for any typeof sub-analysis. Despite similar distribution of 1-, 2-, and
3-vessel disease (VD) in all 3 dose groups (see Table, sta-
tistics not significant), sensitivities/specificities were
also calculated with 3-VD patients excluded yielding
91/71% for dose 3 (94/71% with 3-VD), 89/78% for dose
2 (91/78% with 3-VD), and 94/25% for dose 1 (94/25%
with 3-VD).
Fig. 3 demonstrates a comparable diagnostic perfor-
mance of the MR perfusion technique in the various
myocardial perfusion territories (irrespective of receiver
coil distance). Fig. 4 shows the influence of the number
Fig. 2 Receiver operator characteristics (ROC) curves of MR upslope
data are shown for the detection of coronary artery disease (P50%
diameter stenosis in P 1 vessel by quantitative coronary angiography).
MR upslope data from the subendocardial layer are highly reliable in the
detection of disease when analysis is restricted to the central 3 slices in
patients with adequate image quality (a). Numbers within the plots
represent area under the ROC curve ± standard error for doses 1, 2 and 3
(=D1, D2, D3, respectively). In less restrictive data sets (analysis of all
quality scores, b; and analysis of 5 slices, c), diagnostic performance
tended to decrease for doses 2 and 3. AUC of dose 2 for least restrictive
data (all slices, all quality scores, d) was worst (p < 0.05 vs. dose 2 in a). A
dose of 0.05 mmol/kg (=D1) performed inadequately in all analyses. Due
to comparisons between 3 doses a p < 0.017 is considered significant.
Fig. 3 Diagnostic performance (=sensitivity/specificity of MR perfusion
imaging of pooled doses 2 and 3 to detect P 50% diameter stenoses in the
various coronary arteries by QCA; 44 patients) was similar in the various
perfusion territories and confirms comparable image quality throughout
the left ventricular myocardium. In the anterior and antero-septal wall
(assigned to the left anterior descending coronary artery) 10 segments
were analysed, in the lateral wall (assigned to the left circumflex
coronary artery) 5, and in the inferior and infero-septal wall (assigned to
the right coronary artery) 10 segments were analysed. For the patient-
based analysis (entire heart) all 40 segments per heart were included in
the analysis, which increased sensitivity/specificity.
1662 T.H. Giang et al.of coronary artery involvement on sensitivity and speci-
ficity of MR data. An example is given in Fig. 5.
For all analyses, transmural data performed slightly
worse than subendocardial data. However, sample size
was too small to achieve statistical significance even
after pooling of doses 2 and 3 (AUC of subendocardial
and transmural data: 0.88 ± 0.05 and 0.80 ± 0.05, respec-
tively, not significant). For image registration, contour
drawings, and upslope calculations approximately 10,
5, and 1 min were needed, respectively.
For dose group 1, analysis by both observers yielded
identical sensitivity and specificity. For dose 2, one pa-
tient was missed (=diagnosed as normal) by the analysis
of the second observer (compared with the first ob-
server), whereas no difference was found for the con-
trols (sensitivity/specificity: 82/78%, subendocardial
data, second observer). Finally, for dose 3, one patient
missed by the first observer was detected by the second
observer and no difference was found for the controls
(sensitivity/specificity: 100/71% for second observer).
Mean difference ± SD for subendocardial upslopes (in 3
central slices of 69 patients) determined by observer 1
and 2 for doses 1, 2, and 3 were: 2.1 ± 3.7, 0.1 ± 5.6,
and 0.4 ± 6.7%/s, respectively (for 600, 480, and 576
segments, respectively).Discussion
This study demonstrates (1) that peak signal response
in normal myocardium increases with doses up to
0.15 mmol/kg of an extravascular CM, and (2) a single
hyperaemic examination using doses of 0.10–0.15
mmol/kg and a signal upslope quantification in the sub-
Fig. 4 Sensitivities and specificities for the detection of single-vessel
(a) and multi-vessel disease (b) are shown for the 3 contrast medium
doses. Sensitivities and specificities were particularly high for doses 2 and
3 in multi-vessel disease (not significant vs. single-vessel disease). At a
high sensitivity level, specificity of dose 1 was low (p = 0.07 and p = 0.05
vs. pooled doses 2 and 3 (data not shown) in single and multi-vessel
disease, respectively, Fisher’s exact test).
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tion of CAD.
Diagnostic performance of MR perfusion imaging
The presented MR perfusion technique yields sensitivi-
ties/specificities for the detection of CAD of 91/78%
(AUC 0.91), and 94/71% (AUC 0.86) for the 2 highest
doses of 0.10 and 0.15 mmol/kg of an extravascular CM,
respectively. These high sensitivities/specificities are
obtained from a single hyperaemic study and are in-line
with results of an earlier report10 with a sensitivity/spec-
ificity of 88/86% using a single injection of 0.1 mmol/kg
Gd-DTPA-BMA during hyperaemia. A substantial body of
evidence from the positron emission tomography (PET)
literature supports these findings demonstrating high
correlations between percent area stenosis of epicardial
coronary vessels and maximal hyperaemic blood
flow.14,15 Although an MR perfusion reserve approach
yielded high sensitivity/specificity as well,4 the assess-
ment of hyperaemic perfusion alone confers severaladvantages such as a reduced examination time (avoiding
a second CM injection and the waiting time between in-
jections), a reduced analysis time (no analysis of resting
study), and eliminating the necessity to spatially match
the hyperaemic and resting study for the reserve calcula-
tion, which might be particularly problematic if analysis
is performed for the subendocardium. In addition, myo-
cardial signal response induced by the second CM injec-
tion is influenced by the amount of CM still present in
the myocardium following the first injection, unless com-
plete wash-out is allowed, which however, would prolong
the examination. Finally, hyperaemic perfusion during
vasodilation is decoupled from oxygen demand, while
perfusion reserve also depends on resting haemodynam-
ics,16 which may confound the flow-limiting effect of
epicardial coronary stenoses.
One prerequisite for a reliable analysis of CM wash-in
kinetics is an efficient data correction for inhomogeneous
receiver coil sensitivity, which is achieved by division of
first-pass data by pre-contrast data (Fig. 1). As a result,
sensitivities and specificities for CAD detection are pre-
served even in territories distant from the surface coil.
This might be one major reason for the high overall sensi-
tivities and specificities for detection of CAD of 91–94%
and 71–78% for doses 2 and 3, respectively, and even
higher sensitivities and specificities were achieved for
multi-vessel disease. For comparison, multi-centre sin-
gle-photon emission computed tomography trials yielded
adequate sensitivities of 77–85% but compromised spec-
ificities of 50–58%.17–19 To our knowledge, only one
multi-centre MR perfusion trial has been performed in
the past, which achieved a relatively low sensitivity of
57% with a specificity of 85% (using 75% diameter stenosis
on QCA as a reference).9 These results obtained with 0.04
mmol/kg of a Gd-chelate are in line with the current re-
sults of dose 1. The study population consisting of women
with a low prevalence of CAD may have further contrib-
uted to the rather low test sensitivity in that study.Contrast medium dose and data quality
Despite the involvement of 3 centres with considerable
experience in MR perfusion imaging, data quality was
heterogeneous which led us to apply a scoring system
for quality. Over 80% of artefacts during CM first-pass
were breathing-related and/or degraded by ECG
mistriggering. Another source of image degradation is
related to cardiac coverage. In more apical slices, par-
tial volume artefacts are more relevant, whereas in the
most basal slices, the left atrium and/or the membra-
nous portion of the interventricular septum may be in-
cluded, where CM wash-in kinetics of myocardium do
not apply. In this study triggering was set to every sec-
ond R-wave and interleaved acquisitions occurred dur-
ing all cardiac phases clearly affecting the quality of
the slices acquired during rapid cardiac motion, i.e.,
in early-mid systole and early diastole. Accordingly,
best quality was present in the central 3 slices (minor
partial volume artefacts, no acquisition during rapid
cardiac motion) of studies with a quality score < 4
Fig. 5 Examples of MR perfusion studies for dose 1 (top rows a–m) and dose 3 (bottom rows n–y). For dose 1, a stenosis in the left anterior descending
coronary artery (LAD) is shown on X-ray angiography (arrow in a) with 5 short-axis MR perfusion images at peak bolus effect in h–m demonstrating low
signal areas in the anterior wall (k–l). Corresponding upslope maps are shown in b–d and polar maps for the subendocardial layer are given with
thresholds applied pixel-wise (e) and for entire segments (f) with blue/red encoding for upslope values below/above the thresholds, respectively (the
polar maps show all acquired slices, for ROC analyses only the central 5 slices were used, for reasons see text). For dose 3, stenoses in the small first
diagonal branch of the LAD (arrow in n) and the large left circumflex coronary artery (LCX) are shown (arrowhead in n). For dose 1, note the considerable
noise and reduced dynamic range of signal response (h–m) compared with dose 3 (o–s). Upslope maps and subendocardial polar maps for dose 3 (u–y)
are generated as explained for dose 1. The second patient (dose 3) further demonstrates the limitation of using coronary anatomy as a reference for
perfusion studies: perfusion defects in segment 5 and 6 represent a mismatch with the right coronary artery territory in this patient with a stenosis in the
large LCX.
1664 T.H. Giang et al.(predominantly eliminating breathing artefacts). In
these data with best artefact control, doses 2 and 3
showed superiority over dose 1. This finding demon-
strates the importance of an adequate CM dose to
achieve high upslope values in normally perfused myo-
cardium and thus, to allow its differentiation from
delayed wash-in kinetics in stenosis-dependent myocar-
dium when using semi-automatic analysis.
As in earlier studies,8,10 a trend towards better diag-
nostic performance of subendocardial data in compari-
son with transmural data was found, which indicates
that potential susceptibility artefacts at the blood
pool–myocardium interface, even at 0.15 mmol/kg,
are small and do not compromise the diagnostic perfor-
mance of semi-automatic upslope calculations.Limitations
While perfusion assessment by PET and MR showed a high
agreement,10 the PET technique is not widely available.
Therefore, stenosis anatomy, as assessed by QCA, waschosen as the comparator in this multi-centre setting,
even though a perfect agreement between perfusion im-
aging and QCA cannot be expected and is likely to result
in an underestimation of the diagnostic yield of perfusion
imaging. In particular, assignment of MR perfusion defi-
cits to individual coronary stenoses (as shown in Fig. 3)
may be problematic when performed in a systematic
and blinded fashion as in this study (which did not consid-
er the extent of perfusion territories of individual vessels
nor collaterals).
While sample size allowed to demonstrate inferiority
of dose 1 vs. doses 2 and 3 for detection of CAD, the
study population was too small to detect differences be-
tween subendocardial and transmural data, or to assess
the influence of operators on image quality and test per-
formance. Also, women were underrepresented in this
study (<20%) and test performance cannot be applied di-
rectly to women. The same caveat applies for patients
after percutaneous coronary interventions and for those
with complete left bundle branch block. Results of the
current trial, particularly on how many slices should be
analysed, should not be extrapolated for different pulse
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging 1665sequences or different hardware. Fourteen patients had
to be excluded due to partially missing data. As a conse-
quence, we cannot assess whether exclusions were dis-
proportionate in the 3 dose groups with respect to
diagnosis, data quality or other aspects, and any bias
cannot be excluded with certainty.
In patients with known or suspected CAD, detection
of hypoperfused myocardium is important but addi-
tional information as to whether hypoperfusion is re-
lated to scar tissue or not is essential for an optimal
patient management. Accordingly, a viability assess-
ment by delayed enhancement20,21 should be added
to a perfusion study to allow for a comprehensive diag-
nostic work-up.Conclusions
This study demonstrates a high diagnostic performance
of MR perfusion imaging for the detection of anatomically
defined coronary artery stenoses when performing a
semi-automatic analysis of CM wash-in kinetics into the
subendocardium in combination with CM doses of 0.10–
0.15 mmol/kg. The short examination time of this
stress-only MR protocol and the semi-automatic analysis
are major advantages of the proposed technique. These
multi-centre results also illustrate the importance of
data quality which was inadequate in 14% of studies.
Larger multi-centre trials are needed to further refine
and disseminate the technique.Acknowledgements
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